Fresenius Medical Care AG & Co. KGaA Q3 2026 Earnings Recap

Fresenius Medical Care reported broadly stable third-quarter revenue and earnings, with organic growth in Care Delivery partly offset by lower Value-Based Care revenue and anticipated TDAPA reimbursement headwinds. Shares rose 1.0% after the results, a relatively muted reaction.

Key Takeaways

• Management described third-quarter revenue and earnings as broadly stable; the transcript excerpt does not provide specific financial figures.
• Care Delivery’s organic growth was partly offset by a decline in Value-Based Care revenue. Management attributed the decline to a previously communicated change, but the excerpt cuts off before giving more detail.
• TDAPA reimbursement headwinds were anticipated; management said improving underlying business performance helped offset them.
• The U.S. rollout of the 5008X had reached 348 clinics, or 14% of clinics, by September-end, with about 9,000 machines installed—approximately 16% of the install base. The company remained on track to convert 20% by year-end.
• FDA audits identified findings and observations at company facilities. Management said corrective and preventive actions are being implemented alongside efforts to strengthen quality systems.